Shire May Split Up – But Punting On Bigger Decisions For Now
The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.
The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.